IntraLinks announced the results of the IntraLinks Global Investigator Site survey that looked at the effectiveness of methods currently used for clinical trial document.
The Cole-Parmer IKA BR 10 Bioreactor features an interface that controls all of the photosynthetic variables of lighting, motion, pH value, and temperature. The unit takes up less than half the space of a traditional bioreactor.
PerkinElmer Inc. launched its AxION Mass Spectrometry platform. The AxION hardware and software platform delivers rapid and accurate mass identification and quantification to ensure safer pharmaceutical products.
Celerion announced that its clinical research operations in Belfast and its clinical research and bioanalytical services operations in Lincoln, Nebraska, have been certified by the Brazilian National Health Surveillance Agency (ANVISA).
Scientists have discovered an entirely new way to change the genetic code. The findings may ultimately help researchers alter the course of devastating genetic disorders, such as cystic fibrosis, muscular dystrophy, and many forms of cancer.
ARIAD Pharmaceuticals, Inc. announced the results of preclinical studies on AP26113, showing that AP26113 has a novel profile as a dual inhibitor of ALK and EGFR, an additional validated target in non-small cell lung cancer.
Nulojix, the first new type of drug in more than a decade for keeping transplanted kidneys functioning, has won approval from the Food and Drug Administration.
Researchers in Canada have discovered why dopamine replacement therapy, which is used to manage motor symptoms associated with Parkinson's disease, can, at times, adversely affect cognition.
An analysis in the British Medical Journal said patients who took a version of lung drug Spiriva in clinical trials were 52 percent more likely to die than patients who took a placebo.
Adaptimmune announced it has opened a Phase 1 and Phase 2 cohort, open label clinical trial in metastatic melanoma at Washington University.
In a study at UCLA's Jonsson Comprehensive Cancer Center, researchers found when a common type of prostate cancer was treated with conventional hormone ablation therapy blocking androgen production or androgen receptor (AR) function, the cancer adapted by activating a survival cell signaling pathway.
Eating a low-carbohydrate, high-protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study conducted at the British Columbia Cancer Research Center.
Boehringer Ingelheim Pharmaceuticals and Eli Lilly announced Tradjenta (linagliptin) tablets are available by prescription in pharmacies across the United States.
ProImmune Ltd. has launched ProArray Ultra, a powerful protein and peptide array platform, which allows analysis of more than 30,000 peptides or proteins at once and typically requires only 1 ul of analyte sample.
Lumen Dynamics introduces the X-Cite 200DC for fluorescence microscopy. Designed with a 200-watt DC lamp, the X-Cite 200DC provides outstanding stability from short to long term with a high speed internal shutter for optimum image quality.